|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DIP2A |
Gene summary for DIP2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DIP2A | Gene ID | 23181 |
| Gene name | disco interacting protein 2 homolog A | |
| Gene Alias | C21orf106 | |
| Cytomap | 21q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q14689 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23181 | DIP2A | LZE7T | Human | Esophagus | ESCC | 2.11e-05 | 2.01e-01 | 0.0667 |
| 23181 | DIP2A | LZE8T | Human | Esophagus | ESCC | 2.03e-02 | 4.98e-02 | 0.067 |
| 23181 | DIP2A | LZE22T | Human | Esophagus | ESCC | 4.25e-03 | 1.97e-01 | 0.068 |
| 23181 | DIP2A | LZE24T | Human | Esophagus | ESCC | 7.43e-18 | 5.46e-01 | 0.0596 |
| 23181 | DIP2A | LZE21T | Human | Esophagus | ESCC | 1.41e-02 | 1.47e-01 | 0.0655 |
| 23181 | DIP2A | P1T-E | Human | Esophagus | ESCC | 4.97e-04 | 2.12e-01 | 0.0875 |
| 23181 | DIP2A | P2T-E | Human | Esophagus | ESCC | 1.89e-20 | 2.21e-01 | 0.1177 |
| 23181 | DIP2A | P4T-E | Human | Esophagus | ESCC | 2.11e-15 | 2.74e-01 | 0.1323 |
| 23181 | DIP2A | P5T-E | Human | Esophagus | ESCC | 7.92e-13 | 1.66e-01 | 0.1327 |
| 23181 | DIP2A | P8T-E | Human | Esophagus | ESCC | 1.50e-16 | 1.55e-01 | 0.0889 |
| 23181 | DIP2A | P9T-E | Human | Esophagus | ESCC | 1.35e-10 | 1.45e-01 | 0.1131 |
| 23181 | DIP2A | P10T-E | Human | Esophagus | ESCC | 8.89e-16 | 3.48e-01 | 0.116 |
| 23181 | DIP2A | P11T-E | Human | Esophagus | ESCC | 8.17e-06 | 1.68e-01 | 0.1426 |
| 23181 | DIP2A | P12T-E | Human | Esophagus | ESCC | 3.42e-20 | 2.62e-01 | 0.1122 |
| 23181 | DIP2A | P15T-E | Human | Esophagus | ESCC | 1.16e-13 | 1.31e-01 | 0.1149 |
| 23181 | DIP2A | P16T-E | Human | Esophagus | ESCC | 1.35e-11 | 2.39e-01 | 0.1153 |
| 23181 | DIP2A | P20T-E | Human | Esophagus | ESCC | 2.05e-14 | 1.31e-01 | 0.1124 |
| 23181 | DIP2A | P21T-E | Human | Esophagus | ESCC | 2.51e-20 | 1.91e-01 | 0.1617 |
| 23181 | DIP2A | P22T-E | Human | Esophagus | ESCC | 3.17e-11 | 1.15e-01 | 0.1236 |
| 23181 | DIP2A | P23T-E | Human | Esophagus | ESCC | 2.86e-15 | 2.67e-01 | 0.108 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:010602713 | Oral cavity | NEOLP | neuron projection organization | 22/2005 | 93/18723 | 2.64e-04 | 2.69e-03 | 22 |
| GO:009706113 | Oral cavity | NEOLP | dendritic spine organization | 19/2005 | 84/18723 | 1.20e-03 | 8.85e-03 | 19 |
| GO:19019833 | Oral cavity | NEOLP | regulation of protein acetylation | 17/2005 | 77/18723 | 2.80e-03 | 1.73e-02 | 17 |
| GO:004354331 | Oral cavity | NEOLP | protein acylation | 40/2005 | 243/18723 | 3.85e-03 | 2.21e-02 | 40 |
| GO:000647331 | Oral cavity | NEOLP | protein acetylation | 34/2005 | 201/18723 | 4.76e-03 | 2.61e-02 | 34 |
| GO:000915025 | Oral cavity | NEOLP | purine ribonucleotide metabolic process | 55/2005 | 368/18723 | 6.80e-03 | 3.46e-02 | 55 |
| GO:001839431 | Oral cavity | NEOLP | peptidyl-lysine acetylation | 29/2005 | 169/18723 | 7.09e-03 | 3.60e-02 | 29 |
| GO:000925925 | Oral cavity | NEOLP | ribonucleotide metabolic process | 57/2005 | 385/18723 | 7.23e-03 | 3.66e-02 | 57 |
| GO:001969325 | Oral cavity | NEOLP | ribose phosphate metabolic process | 58/2005 | 396/18723 | 8.46e-03 | 4.13e-02 | 58 |
| GO:000915018 | Prostate | BPH | purine ribonucleotide metabolic process | 107/3107 | 368/18723 | 1.18e-09 | 5.19e-08 | 107 |
| GO:000925917 | Prostate | BPH | ribonucleotide metabolic process | 108/3107 | 385/18723 | 8.73e-09 | 2.97e-07 | 108 |
| GO:000616318 | Prostate | BPH | purine nucleotide metabolic process | 109/3107 | 396/18723 | 2.28e-08 | 6.94e-07 | 109 |
| GO:001969317 | Prostate | BPH | ribose phosphate metabolic process | 109/3107 | 396/18723 | 2.28e-08 | 6.94e-07 | 109 |
| GO:007252118 | Prostate | BPH | purine-containing compound metabolic process | 113/3107 | 416/18723 | 2.77e-08 | 8.13e-07 | 113 |
| GO:00609966 | Prostate | BPH | dendritic spine development | 37/3107 | 99/18723 | 5.22e-07 | 1.04e-05 | 37 |
| GO:00163589 | Prostate | BPH | dendrite development | 71/3107 | 243/18723 | 5.73e-07 | 1.14e-05 | 71 |
| GO:000915217 | Prostate | BPH | purine ribonucleotide biosynthetic process | 52/3107 | 169/18723 | 3.46e-06 | 5.42e-05 | 52 |
| GO:00182055 | Prostate | BPH | peptidyl-lysine modification | 96/3107 | 376/18723 | 5.70e-06 | 8.39e-05 | 96 |
| GO:000911717 | Prostate | BPH | nucleotide metabolic process | 118/3107 | 489/18723 | 9.68e-06 | 1.35e-04 | 118 |
| GO:00488136 | Prostate | BPH | dendrite morphogenesis | 45/3107 | 146/18723 | 1.46e-05 | 1.88e-04 | 45 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DIP2A | SNV | Missense_Mutation | rs763963275 | c.1729G>A | p.Val577Met | p.V577M | Q14689 | protein_coding | deleterious(0.01) | probably_damaging(0.955) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| DIP2A | SNV | Missense_Mutation | c.3067N>T | p.His1023Tyr | p.H1023Y | Q14689 | protein_coding | tolerated(0.12) | possibly_damaging(0.798) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DIP2A | SNV | Missense_Mutation | c.160C>G | p.Gln54Glu | p.Q54E | Q14689 | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| DIP2A | SNV | Missense_Mutation | c.3214G>A | p.Val1072Met | p.V1072M | Q14689 | protein_coding | tolerated(0.1) | probably_damaging(0.964) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| DIP2A | SNV | Missense_Mutation | novel | c.2981N>T | p.Arg994Leu | p.R994L | Q14689 | protein_coding | deleterious(0.02) | probably_damaging(0.945) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DIP2A | SNV | Missense_Mutation | c.4448G>A | p.Arg1483Lys | p.R1483K | Q14689 | protein_coding | tolerated(1) | benign(0.006) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| DIP2A | SNV | Missense_Mutation | novel | c.4198T>C | p.Tyr1400His | p.Y1400H | Q14689 | protein_coding | deleterious(0) | benign(0.443) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| DIP2A | SNV | Missense_Mutation | c.2386A>T | p.Ile796Phe | p.I796F | Q14689 | protein_coding | deleterious(0.01) | possibly_damaging(0.493) | TCGA-D8-A1XR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| DIP2A | SNV | Missense_Mutation | rs377394571 | c.434C>G | p.Ser145Cys | p.S145C | Q14689 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-D8-A1XY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | tamoxiphen | SD |
| DIP2A | SNV | Missense_Mutation | c.968N>G | p.Glu323Gly | p.E323G | Q14689 | protein_coding | deleterious(0.03) | possibly_damaging(0.858) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |